In this article, we will be taking a look at the 10 Popular Penny Stocks on Robinhood to Watch in 2026.

Penny stocks remain one of the market’s most debated investment areas, offering the potential for enormous gains while carrying equally significant risks. While many hedge fund managers and billionaire investors caution that speculative small-cap stocks might crash when fundamentals don’t live up to expectations, others think underappreciated businesses can eventually turn into remarkable long-term successes. The renowned investor Peter Lynch made a name for himself by spotting underappreciated companies before Wall Street saw their potential. Over the course of 13 years, his Magellan Fund produced an average return of about 29.2%.

Purchasing the cheapest shares is no longer the only way to take advantage of penny stock opportunities. Rather, investors are paying more attention to smaller businesses whose balance sheets, profits, and general business quality are improving more quickly than the market anticipates. Franklin Templeton’s Royce Investment Partners believes “2026 could be the year that small-caps reassert themselves,” arguing that both small-cap quality and value are positioned for meaningful rebounds in 2026. AllianceBernstein shares a similar outlook, stating that small-cap earnings growth is expected to outpace large companies in 2026 and may still be widely underestimated by the market. T. Rowe Price also argues that the recent rebound in small caps is being supported not only by improving sentiment but also by strengthening fundamentals.

Recent academic research further explains why penny stocks continue attracting investors despite their volatility. According to a study published on arXiv that looked at 167 small businesses listed on India’s National Stock Exchange, smaller market-cap penny companies did significantly better than larger penny stocks, and lower P/E and lower price-to-book stocks also generated higher returns. A Journal of Banking & Finance study found that over 30% of severely shorted businesses also had significant hedge-fund ownership, highlighting the intense discussion and speculation that often surround risky stocks.

Investors are paying more attention to penny stocks with stronger fundamentals, analyst support, manageable balance sheets, and realistic long-term growth potential rather than transient trading hype as improving earnings cycles start to support smaller companies after years of being ignored.

With that being said, let’s now take a look at the penny stocks on Robinhood.

Our Methodology

For our methodology, we screened for Robinhood stocks that are under $5. From the list, we picked stocks with the most recent news and developments, and then we ranked them in ascending order based on their last close as of May 26.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

Here is our list of the 10 popular penny stocks on Robinhood to watch in 2026.

10. ESS Tech, Inc. (NYSE:GWH)

Stock Price as of Last Close of May 26: $1.01

ESS Tech, Inc. (NYSE:GWH) is one of the popular penny stocks on Robinhood on this list.

TheFly reported on May 18 that Roth Capital reduced its price target on GWH from $2.50 to $2 while maintaining a Buy rating. The adjustment followed the company’s softer first-quarter results as GWH continues shifting toward commercialization of its Energy Base platform, although management pointed to ongoing strategic developments involving Project New Horizon alongside SRP and Google.

Moreover, the company’s growing commercial momentum was further reflected in a significant infrastructure achievement announced on May 5, 2026. ESS Tech, Inc. (NYSE:GWH) revealed that it had completed the commissioning of two iron flow battery systems for Turlock Irrigation District in California’s Central Valley. The installation combines ESS’s long-duration energy storage technology with solar panels positioned above irrigation canals, creating a dual-purpose system aimed at producing renewable electricity while limiting water evaporation. The project highlights the expanding role of long-duration storage in supporting utility and infrastructure operations that require dependable and flexible energy delivery.

GWH stated that the deployment demonstrates how its iron flow battery systems can improve renewable energy management while contributing to broader conservation efforts. The initiative also reflects increasing interest among utilities and water agencies in integrated energy and water solutions. GWH’s technology relies on iron, salt, and water materials designed for safe stationary energy storage applications.

ESS Tech, Inc. (NYSE:GWH) is a clean-energy company that develops long-duration iron flow batteries for commercial and utility-scale energy storage.

9. Fold Holdings, Inc. (NASDAQ:FLD)

Stock Price as of Last Close of May 26: $1.02

Fold Holdings, Inc. (NASDAQ:FLD) is another popular penny stock on this list.

TheFly reported on May 13 that Cantor Fitzgerald reduced its price objective on FLD from $2 to $1.70 while reiterating an Overweight rating on the stock.

Fold Holdings, Inc. (NASDAQ:FLD) released its first quarter 2026 financial results on May 12, reporting weaker year-over-year performance amid softer conditions across the broader Bitcoin market. The company posted revenue of $5.6 million, representing a decline of more than 21% from the prior-year period, while transaction volume fell 32% to $172 million. Fold also recorded a net loss of $29.2 million during the quarter and ended the period with 826 BTC in its treasury holdings.

Management stated that lower Bitcoin prices negatively affected trading activity, transaction volumes, and customer engagement throughout the industry. Despite the challenging environment, the company continued expanding its product ecosystem, including the rollout of its Bitcoin Rewards Credit Card, which now has more than 1,000 cards in circulation. Fold also highlighted strong early customer engagement trends and increasing cross-platform adoption among users.

Additionally, the business emphasized ongoing expansion plans for its Bitcoin Gift Card initiative, which management believes could support broader customer acquisition and increase long-term engagement across the Fold platform.

Fold Holdings, Inc. (NASDAQ:FLD) is a Bitcoin financial services company that helps consumers earn, save, and spend Bitcoin in everyday transactions.

8. FibroBiologics, Inc. (NASDAQ:FBLG)

Stock Price as of Last Close of May 26: $1.06

FibroBiologics, Inc. (NASDAQ:FBLG) is among the most popular penny stocks.

TheFly reported on May 22 that FBLG released preclinical findings from its CYPS317 psoriasis program at the Society for Investigative Dermatology 2026 Annual Meeting. The company reported that its fibroblast spheroid therapy reduced disease severity in psoriasis mouse models while showing a stronger systemic safety profile compared to single-cell approaches.

Additional results demonstrated sustained therapeutic activity with booster dosing, including reductions in PASI scores, lower immune cell accumulation, and protection against skin thickening and inflammatory infiltration. FBLG stated that the data support CYPS317’s potential as a targeted immunomodulatory treatment approach for chronic psoriasis without broad immune suppression.

Separately, earlier on May 11, FibroBiologics, Inc. (NASDAQ:FBLG) broadened the scope of its fibroblast therapeutic platform to include Hantavirus pulmonary syndrome, a severe respiratory disease associated with high mortality rates. The company stated that the expansion builds on prior preclinical research involving acute respiratory distress syndrome, where fibroblasts demonstrated potential to reduce inflammatory signaling, repair tissue damage, and improve endothelial barrier function.

FBLG believes the similarities between HPS-related lung injury and ARDS make its fibroblast-based approach suitable for further investigation in Hantavirus models. The company is currently assessing the platform’s impact on cytokine activity, vascular permeability, and respiratory tissue damage while exploring future regulatory discussions.

FibroBiologics, Inc. (NASDAQ:FBLG) is a clinical-stage biotech company focused on regenerative medicine, developing fibroblast-based therapies for chronic diseases.

7. TScan Therapeutics, Inc. (NASDAQ:TCRX)

Stock Price as of Last Close of May 26: $1.07

TScan Therapeutics, Inc. (NASDAQ:TCRX) is one of the most popular penny stocks. 

TheFly reported on May 6 that TCRX announced its first-quarter 2026 financial results, covering the period ended March 31, 2026, along with a corporate update. The company reported revenue of $1.0 million versus $2.2 million in the prior-year quarter, reflecting lower research activity tied to its collaboration with Amgen. Research and development expenses totaled $21.9 million compared to $29.8 million a year earlier, while general and administrative expenses were $8.2 million versus $8.6 million, driven mainly by reduced professional costs and timing of spending.

The corporation’s net loss improved to $28.7 million from $34.1 million, supported by $0.5 million in net interest income compared with $2.1 million previously. Cash and cash equivalents stood at $128.1 million as of March 31, 2026, excluding $5.0 million restricted cash, with a runway expected into the second half of 2027. The update also outlined pipeline progress across heme malignancies, solid tumors, and autoimmune programs, including upcoming clinical milestones and preclinical developments.

In separate news, on April  27, TScan Therapeutics, Inc. (NASDAQ:TCRX) announced acceptance of a scientific abstract for presentation at the ASGCT 29th Annual Meeting in Boston, held May 11–15, 2026. The poster focuses on CD45-targeted TCR-T therapies aimed at eliminating residual disease and reducing relapse risk after allogeneic stem cell transplantation.

TScan Therapeutics, Inc. (NASDAQ:TCRX) is a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered therapies for cancer and autoimmune diseases. It uses a proprietary platform to identify immune targets and design treatments that activate the body’s own T cells to fight disease.

6. Lucid Diagnostics Inc. (NASDAQ:LUCD)

Stock Price as of Last Close of May 26: $1.11

Lucid Diagnostics Inc. (NASDAQ:LUCD) is also on this list of popular penny stocks.

TheFly reported on May 15 that Maxim Group reduced its price target on LUCD from $3 to $2 while maintaining a Buy rating following a weaker-than-expected first-quarter revenue report. The company continues to await a Medicare local coverage determination decision, but is actively advancing its commercialization strategy in preparation for potential reimbursement approval, according to the analyst note.

Lucid Diagnostics Inc. (NASDAQ:LUCD) issued its first-quarter 2026 financial results on May 14, alongside a broader business update for the period ended March 31, 2026. The company reported $1.3 million in revenue generated from EsoGuard esophageal DNA testing, based on 3,177 tests processed during the quarter. Operating expenses totaled approximately $13.4 million, including $1.4 million in stock-based compensation, resulting in a GAAP net loss of about $23.6 million attributable to common shareholders. On a non-GAAP basis, adjusted loss was approximately $10.5 million.

The company also reported cash and equivalents of $27.9 million at quarter’s end, down from $34.7 million at the end of the prior year, while highlighting additional financing activity that improved liquidity and extended projected runway into 2027. Operational updates included expanded clinical and commercial engagement for EsoGuard and EsoCheck, increased participation at major medical conferences, and ongoing adoption efforts supported by emerging clinical guideline developments favoring non-endoscopic testing approaches.

Lucid Diagnostics Inc. (NASDAQ:LUCD) is a commercial-stage diagnostics company focused on early detection of esophageal precancer in patients with chronic GERD, aiming to help prevent progression to esophageal cancer.

Click to continue reading and see the 5 Popular Penny Stocks on Robinhood to Watch in 2026.

Disclosure: None. Follow Insider Monkey on Google News.